{"id":"W4365504267","doi":"10.1158/1078-0432.ccr-22-3145","title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; EMD Serono; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Seagen; Castle Biosciences; University of Miami; Pfizer; Incyte; BeiGene; Regeneron Pharmaceuticals; Mylan; Les Laboratories Pierre Fabre; Sun Pharma; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Qbiotics; Samsung; Bristol-Myers Squibb; AstraZeneca; PharmaMar; Jounce Therapeutics; Celgene","keywords":"Ipilimumab; Nivolumab; Medicine; Adjuvant; Melanoma; Oncology; Stage (stratigraphy); Internal medicine; Biomarker; Cancer; Immunotherapy; Cancer research; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003664173,0.0002085134,0.0006005234,0.0005856025,0.0001699413,0.00007537982,0.0002492043,0.0002719009,0.0008121379],"category_scores_gemma":[0.003269203,0.0001859457,0.0001162384,0.001568685,0.0004260906,0.00006444987,0.0005448973,0.001180196,0.0005317795],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003405176,"about_ca_system_score_gemma":0.000322095,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005671023,"about_ca_topic_score_gemma":0.004259326,"domain_scores_codex":[0.9956387,0.0005920144,0.0009591244,0.001017879,0.0009815913,0.0008107256],"domain_scores_gemma":[0.9957955,0.002589538,0.0001062253,0.0008147584,0.0002396657,0.0004542963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.3807085,0.002025427,0.02316161,0.0005110126,0.001329265,0.008296186,0.002066848,0.00004331972,0.01119973,0.0002223109,0.2277963,0.3426395],"study_design_scores_gemma":[0.1125282,0.003600384,0.6941756,0.0006015471,0.0001128341,0.000008934843,0.00223845,0.004277679,0.001205987,0.0001317042,0.1805943,0.0005244014],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861242,0.0004671256,0.000002123231,0.003499634,0.0009578987,0.001135003,0.0001561316,0.0002189909,0.00743887],"genre_scores_gemma":[0.9786029,0.003244027,0.00004606354,0.00009103559,0.0004375408,0.0001115251,0.000125121,0.00005299954,0.01728872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.671014,"threshold_uncertainty_score":0.8892341,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2688114832801393,"score_gpt":0.4950586956507886,"score_spread":0.2262472123706494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}